(Q37327097)

19 August 2017

1 reference

title

Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients? (English)

1 reference

19 August 2017

1 reference

Miguel Salavert

1

1 reference

19 August 2017

publication date

1 November 2008

1 reference

International Journal of Antimicrobial Agents

19 August 2017

published in

1 reference

19 August 2017

volume

32 Suppl 2

1 reference

19 August 2017

page(s)

S149-53

1 reference

Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Fungal infections in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

[Voriconazole for the therapy of mycoses in recipients of solid organ transplants]

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Fungal infections in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Aspergillus infections in lung transplant recipients: risk factors and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Aspergillus infections in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Fungal infections after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Role of new antifungal agents in prophylaxis of mycoses in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Considerations in the approach to invasive fungal infection in patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Late-onset invasive aspergillosis in organ transplant recipients in the current era.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Invasive aspergillosis in the recipients of liver retransplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Antifungal agents for preventing fungal infections in non-neutropenic critically-ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

A randomized, prospective, double-blinded evaluation of selective bowel decontamination in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Early bacterial and fungal infections in liver transplantation after oral selective bowel decontamination

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study1

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Antifungal management practices in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

Preemptive treatment of fungal infection based on plasma (1 --> 3)beta-D-glucan levels after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2808%2970017-7

7 January 2021

10.1016/S0924-8579(08)70017-7

Identifiers

DOI

1 reference

19 August 2017

1 reference